Loading
Senseonics Holdings, Inc. Stock: price and insider trades · United States
1 insider bought €108k of shares over the last 90 days, the latest filed 20 Aug 2026.
Senseonics Holdings, Inc.: what insiders have been doing
Senseonics Holdings, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Between 18 October 2025 and 18 October 2026, 11 insiders published 28 filings.
No insider sold shares on the market over the period. Instead, the filings list 7 purchases totalling €529k, made by 4 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. One trade stands out by size: a purchase of €108k from Roeder Douglas A, disclosed on 20 August 2026, or 0.023% of market capitalisation. On the buying side, the filings list 2 senior executives, 1 finance chief and 1 chief executive among the declarants.
The data flag 6 purchases as part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The last insider purchase was made public on 20 August 2026, 58 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 28 filings here. Over the whole record (from 2021), the tally stands at 12 purchases and 10 sales. The 10-K for the year ended 31 December 2025 shows 35.3 m USD of revenue and -69.1 m USD of net income.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
237
Thresholds
n/a
Buy Volume
€968,038
12 ops. · all time
Sell Volume
€2M
10 ops. · all time
Who traded when
BuySaleDouglas A. Roeder5 buys
Timothy T. Goodnow3 buys
Frederick T. Sullivan2 buys
Edelman Steven1 buy
Since the insiders bought
- -16.0%Entry US$9.71 · Close 16 Oct 2026 US$8.16
- +11.6%Entry US$6.49 · Close at T+90 US$7.24
- +21.1%Entry US$6.26 · Close at T+90 US$7.58
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Senseonics Holdings, Inc. Buy (bullish), based on 6 analysts. Average price target: US$13.67.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,506 of 24,148 companies
23.2
score / 100
Value13
Quality34
FCF yld-14%
Earn yld-16%
EV/EBITDA·
ROE-118%
Gross mgn45%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$8.23
Analyst consensus
6 analystsBuy
US$9.00Target US$13.67(+66%)US$18.00
Income statement
RevenueUS$35.3M
Gross profitUS$15.8M45% margin
EBITDA-US$62.7M-178% margin
Net income-US$69.1M-225.3% margin
Valuation
PER (forward)-4.2x
P/Book4.8x
Beta1.03
Balance sheet & cash
Market capUS$435.2M
Total debtUS$41.4M
Free Cash Flow-US$60.2M
Debt / Equity70%
Profitability & ownership
ROE-118.2%
ROA-41.4%
% insiders9.9%
% institutions39.6%
Last declaration on 5 October 2026
Declarations237 total
1,480 shares@ US$9.960.0027% mcap1.8% of flowCommon StockSEC:0001270735-26-000016:0
1,418 shares@ US$9.960.0026% mcap6.9% of flowCommon StockSEC:0001666972-26-000010:0
815 shares@ US$9.960.0015% mcap6.8% of flowCommon StockSEC:0001666995-26-000010:0
1,292 shares@ US$9.960.0024% mcap7.2% of flowCommon StockSEC:0001683354-26-000010:0
13,953.284 shares@ US$8.980.023% mcap15.1% of flowCommon StockSEC:0001270735-26-000014:0
Canonical exit: 17 Nov 2026 (T+90)
9,852 shares0Common StockSEC:0001666964-26-000002:0
9,852 shares0Common StockSEC:0001666972-26-000006:0
553,701 shares0Common StockSEC:0001667588-26-000006:0
90,253 shares0Common StockSEC:0001542377-26-000002:0
1,221 shares@ US$6.657.1% of flowCommon StockSEC:0001666995-26-000004:0
2,218 shares@ US$6.651.8% of flowCommon StockSEC:0001270735-26-000006:0
1,936 shares@ US$6.657.6% of flowCommon StockSEC:0001683354-26-000004:0
2,124 shares@ US$6.657.3% of flowCommon StockSEC:0001666972-26-000004:0
17,225 shares@ US$5.796.2% of flowCommon StockSEC:0001667588-26-000002:0
Canonical exit: 11 Jun 2026 (T+90)
17,500 shares@ US$5.7312.2% of flowCommon StockSEC:0001270735-26-000004:0
Canonical exit: 11 Jun 2026 (T+90)
2,504 shares@ US$5.891.8% of flowCommon StockSEC:0001270735-26-000002:0
2,185 shares@ US$5.894.0% of flowCommon StockSEC:0001683354-26-000002:0
1,379 shares@ US$5.892.7% of flowCommon StockSEC:0001666995-26-000002:0
2,398 shares@ US$5.894.4% of flowCommon StockSEC:0001666972-26-000002:0
4,605 shares@ US$6.264.7% of flowCommon StockSEC:0001769791-25-000004:0
10,317 shares@ US$6.267.1% of flowCommon StockSEC:0001667593-25-000004:0
27,067 shares@ US$6.267.4% of flowCommon StockSEC:0001667588-25-000006:0
5,997 shares@ US$6.2610.0% of flowCommon StockSEC:0001552047-25-000003:0
6,402 shares@ US$6.2655.6% of flowCommon StockSEC:0001944539-25-000006:0
10,000 shares@ US$6.5520.9% of flowCommon StockSEC:0001683354-25-000006:0
Canonical exit: 8 Feb 2026 (T+90)
25 of 237 declarations
About Senseonics Holdings, Inc.
Senseonics Holdings, Inc. is a U.S.-listed medtech company trading on NASDAQ under the ticker SENS. Headquartered in Germantown, Maryland, United States, the company focuses on the development, manufacturing, and commercialization of long-term implantable continuous glucose monitoring (CGM) systems for people living with diabetes. Its core franchise is the Eversense family, a differentiated CGM platform built around an implantable sensor placed under the skin, paired with a wearable transmitter and mobile app. This design sets Senseonics apart from conventional external CGM systems and is central to its investment case. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1616543/000110465926022298/sens-20251231x10k.htm?utm_source=openai))
From a corporate history standpoint, Senseonics has been built around proprietary implantable sensor technology designed to improve glucose monitoring convenience and reduce the frequency of sensor replacement. The company is organized as a Delaware corporation and has long operated from its Maryland base. Over time, it expanded its commercial footprint through successive Eversense iterations, including Eversense E3, which was FDA-approved in February 2022, and Eversense 365, which was cleared for sale in the United States in September 2024. Those milestones matter because they show the company’s move from a single-product innovator toward a broader commercial diabetes-technology platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1616543/000155837025006983/sens-20250331x10q.htm?utm_source=openai))
Read moreShow less
Operationally, Senseonics is still largely a focused, one-platform company centered on diabetes care. Its business includes development, manufacturing, and commercialization of implantable CGM systems, as well as future-generation programs such as Gemini and Freedom referenced in regulatory filings. The company uses a hybrid commercial model, combining direct commercialization with third-party distribution partnerships in markets where those partners already have sales infrastructure and healthcare relationships. That structure allows Senseonics to pursue the U.S. market while also maintaining a presence in select overseas markets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1616543/000110465926022298/sens-20251231x10k.htm?utm_source=openai))
In competitive terms, Senseonics occupies a specialized niche within the broader CGM market. Its key differentiator is the long duration of its implantable sensors and the convenience proposition associated with fewer sensor changes. The flip side is that adoption depends heavily on insurance coverage, physician awareness, and access to trained inserters. In other words, the technology is differentiated, but commercialization remains execution-sensitive. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001616543/000110465926022298/sens-20251231x10k.htm?utm_source=openai))
Recent developments are particularly important for investors. In 2026, Senseonics completed the transition of U.S. commercial responsibility for Eversense back to the company from Ascensia, meaning the company now captures the U.S. product revenue directly. Management has also continued to emphasize the rollout of Eversense 365, the expansion of payer coverage, and further commercialization in Europe and EMEA. These are meaningful near-term catalysts because they influence revenue mix, operating leverage, and the sustainability of growth. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001616543/000110465926022298/sens-20251231x10k.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
